

**Discussions with leaders:** Ken Herrmann talks with Frans van Houten, Chief Executive Officer of Royal Philips Electronics. . . . . **Page 1697**

**Lung  $^{18}\text{F}$ -FDG PET recommendations:** Chen and colleagues from 7 international PET centers provide evidence-based consensus recommendations for patient preparation, scanning protocol design, and imaging data analysis to improve standardization, uniform data collection, and interpretation in lung imaging. . . . . **Page 1701**

**Nuclear imaging of bacterial infection:** Polvoy and colleagues offer an educational overview of current structural and functional imaging techniques for diagnosis of bacterial infection and present several new radiotracers in development, with emphasis on probes targeting bacteria-specific metabolism. . . . . **Page 1708**

**PET/CT in COVID-19:** Foster and colleagues report on the first human PET/CT images using an  $^{18}\text{F}$ -labeled integrin  $\alpha_v\beta_6$ -binding peptide in a patient 2 months after the acute phase of SARS-CoV-2 infection and describe potential for diagnosis and monitoring. . . . . **Page 1717**

**Molecular targeting of COVID-19:** Pillarsetty and colleagues explore the use of  $^{131}\text{I}$ -labeled CR3022, a human antibody that binds to SARS-CoV-2, as a molecularly targeted radiotherapeutic. . . . . **Page 1720**

**LDR and COVID-19:** In a letter to the editor, Højilund-Carlson and colleagues call attention to the potential for low-dose radiation in easing disease course and reducing the need for intensive care in patients with COVID-19. . . . . **Page 1724**

**Autoimmune encephalitis and SARS-CoV-2:** Grimaldi and colleagues provide a clinical review of a 72-y-old man with concomitant autoimmune encephalitis and COVID-19 infection and describe potential advantages of  $^{18}\text{F}$ -FDG PET in such a context. . . . . **Page 1726**

**Radioisotopic lobectomy in DTC:** Piccardo and colleagues detail the results of a systematic review and metaanalysis of studies on the performance of  $^{131}\text{I}$  therapy in differentiated thyroid cancer patients requiring completion treatment after lobectomy. . . . . **Page 1730**

**SIRT vs. sorafenib for HCC:** Venerito and colleagues report on a metaanalysis assessing whether overall survival with selective internal radiation therapy, as monotherapy or followed by sorafenib, is noninferior to sorafenib in advanced hepatocellular cancer. . . . . **Page 1736**

**Imaging proliferation in liver cancer:** Sharma and colleagues investigate the efficacy of  $^{18}\text{F}$ -FLT PET in determining response to transarterial chemoembolization in hepatocellular carcinoma and evaluate new techniques for lesion detection. . . . . **Page 1743**

**$^{68}\text{Ga}$ -NeoBOMB1 in GISTs:** Gruber and colleagues review the outcome of a phase I/IIa clinical trial on safety, pharmacokinetics, and preliminary imaging with this gastrin-releasing peptide receptor antagonist in patients with oligometastatic gastrointestinal stromal tumors. . . . . **Page 1749**

**cCPE peptides for imaging claudin-4:** Torres and colleagues describe basic science investigations using optimized *Clostridium perfringens* enterotoxin-based SPECT imaging agents as targeting vectors for in vivo imaging of claudin-4 overexpression in pancreatic cancer. . . . . **Page 1756**

**SSTR-PET AUC updates:** Hope summarizes recent updates to appropriate use criteria for somatostatin receptor PET imaging, including  $^{64}\text{Cu}$ -DOTATATE approval, a new indication, and guidance on numbers of PET studies in patients with neuroendocrine tumors. . . . . **Page 1764**

**CXCR4 imaging of CNS lymphoma:** Herhaus and colleagues explore the potential of the PET tracer  $^{68}\text{Ga}$ -pentixafor in patients with central nervous system involvement of B-cell lymphoma and highlight potential for theranostic approaches, including response and risk assessment. . . . . **Page 1765**

**$^{177}\text{Lu}$ -EB-PSMA therapy in mCRPC:** Zang and colleagues detail studies assessing the safety and therapeutic response to  $^{177}\text{Lu}$ -labeled Evans blue-modified prostate-specific membrane antigen-617 treatment with escalating doses in patients with metastatic castration-resistant prostate cancer. . . . . **Page 1772**

**PSMA PET accuracy:** Chiu and colleagues evaluate the diagnostic accuracy of  $^{68}\text{Ga}$ -PSMA-11 PET for osseous prostate cancer metastases and look at improvement of bone uptake interpretation using semiquantitative metrics. . . . . **Page 1779**

**PSMA PET/CT tumor volume in prostate cancer:** Seifert and colleagues propose and introduce software that enables semiautomated quantification of prostate-specific membrane antigen PET biomarkers such as whole-body tumor volume. . . . . **Page 1786**

**$^{68}\text{Ga}$ -PSMA-11 PET in biochemical recurrence:** Fendler and colleagues characterize the impact of prostate-specific membrane antigen ligand

PET imaging on management of recurrent prostate cancer in a large prospective cohort. . . . . **Page 1793**

**$^{67}\text{Cu}$ -CuSARtATE for radionuclide therapy:** Cullinane and colleagues assess the antitumor efficacy of  $^{67}\text{Cu}$ -CuSARtATE in a preclinical model of neuroendocrine tumors and compare it with the standard peptide receptor radionuclide therapy agent  $^{177}\text{Lu}$ -LuDOTA-Tyr<sup>3</sup>-octreotate. . . . . **Page 1800**

**$^{18}\text{F}$ -FGlc-FAPI PET imaging:** Toms and colleagues describe radiosynthesis and preclinical evaluation of an  $^{18}\text{F}$ -labeled glycosylated fibroblast-activation protein inhibitor with potential for PET imaging of FAP-related diseases, including cancer, arthritis, heart diseases, and pulmonary fibrosis. . . . . **Page 1806**

**Amyloid PET in dementia:** Shi and colleagues share the results of a multicenter study in China estimating the prevalence of  $\beta$ -amyloid deposits on PET in a variety of dementia syndromes and mild cognitive impairment within a large memory clinic population. . . . . **Page 1814**

**PVEC of longitudinal amyloid PET:** Rullmann and colleagues investigate the effect of partial-volume effect correction on the shape of the  $\beta$ -amyloid curve in Alzheimer disease in a longitudinal analysis of amyloid-sensitive PET data. . . . . **Page 1820**

**A $\beta$  plaque asymmetry in mice:** Sacher and colleagues detail amyloid- $\beta$  asymmetries in 5 A $\beta$  mouse models examined by small-animal PET and test whether such asymmetries are associated with microglial activation. . . . . **Page 1825**

**V/Q planar imaging versus V/Q SPECT:** Wang and colleagues compare the diagnostic performances of ventilation-perfusion planar imaging and V/Q SPECT to determine whether combining perfusion SPECT with low-dose CT is equally effective in chronic thromboembolic pulmonary hypertension. . . . . **Page 1832**

**$^{18}\text{F}$ -BMS-986192 PD-L1 PET:** Stutvoet and colleagues assess the utility of this adnectin-based human programmed cell death ligand 1 tracer to detect different PD-L1 expression levels and therapy-induced changes in in tumors. . . . . **Page 1839**

**Radioiodinated trametinib:** Pratt and colleagues report on various radiolabeled analogs of this potent allosteric inhibitor of mitogen-activated protein kinase/extracellular-signal-regulated kinase with the potential for imaging to monitor therapy resistance and assess drug distribution. . . . . **Page 1845**